EMEA-001636-PIP01-14-M03
Key facts
Invented name |
Verquvo
|
Active substance |
Vericiguat
|
Therapeutic area |
Cardiovascular diseases
|
Decision number |
P/0454/2022
|
PIP number |
EMEA-001636-PIP01-14-M03
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of left ventricular failure
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Bayer AG
Email: pediatrics.medical-affairs-europe@bayer.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|